FDA Seeks Input On Acceptable Trial Design For Assessing Predictive Biomarkers

The Oncologic Drugs Advisory Committee will determine the legitimacy of retrospective trials used to determine predictive biomarkers during review of K-ras data for Erbitux and Vectibix.